Günlük

Tesamorelin and Egrifta

Tesamorelin is the ingredient named on Egrifta. Egrifta is a prescription product with a current label. The vial on this shop is neither the brand nor the prescription. This note quotes the label that was opened, then says what the research listing is. It does not copy the labeled dose, and it does not turn trial tables into a reader schedule.

The shop fact is short. The catalog name is "Tesamorelin 5mg." The full name is "Tesamorelin." One vial is $50. Twelve are $500. The page is Tesamorelin 5mg. The rest of this article is about not confusing that line with Egrifta.

Tesamorelin on the Egrifta label

The label opened for this article is DailyMed's entry for EGRIFTA SV, tesamorelin kit, NDC 62064-241-30, packager Theratechnologies Inc., category human prescription drug label, marketing status biologic licensing application. DailyMed shows the label updated July 29, 2026. The highlights page gives initial U.S. approval as 2010. The page is https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224.

Section 11 of that label describes the substance. "Tesamorelin is a human growth hormone-releasing factor (GRF) analog produced synthetically. It is comprised of the 44 amino acid sequence of human GRF and a hexenoyl moiety, a C6 chain with a double bond at position 3, attached to the tyrosine residue at the N-terminal part of the molecule. Tesamorelin is prepared as an acetate salt." The same section gives the molecular formula of tesamorelin acetate as C221H366N72O67S • x C2H4O2 (x ≈ 7) and a molecular weight, as free base equivalent, of 5135.9 Da.

Section 12.1 says: "In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF." It then says: "Growth hormone-releasing factor (GHRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic." It says some, but not all, of GH's effects "are primarily mediated by IGF-1 produced in the liver and in peripheral tissues."

Section 12.2 says: "Tesamorelin stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels." Those sentences describe Egrifta's ingredient on Egrifta's label. They are not a finding about a research vial. Exposure numbers, half-life, and antibody tables on that label stay with that label.

The Egrifta indication, in the label's words

The highlights give the indication in one sentence. "EGRIFTA SV is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy."

Section 1 repeats the indication without the drug-class clause. "EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy."

That is the approved use on the label that was opened. This note does not widen the sentence to weight loss in general. A named indication on a prescription label is not a reason to use a different container. The highlights call the product a prescription for subcutaneous use, supplied as a kit. That identifies Egrifta SV. It is not repeated below as steps. A separate DailyMed kit, EGRIFTA WR, was not the label quoted here.

What Egrifta is not, on the same label

Directly under the indication, the highlights list limitations of use. "Long-term cardiovascular safety of EGRIFTA SV has not been established." "Not indicated for weight loss management." "There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV."

Section 1 expands the weight-loss line. "EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect." It also says to consider risk and benefit of continuing treatment in patients who have not had a reduction in visceral adipose tissue, because long-term cardiovascular safety "has not been established."

The highlights say EGRIFTA SV is contraindicated in patients with disruption of the hypothalamic-pituitary axis, patients with active malignancy, patients with known hypersensitivity to tesamorelin or the excipients in EGRIFTA SV, and pregnancy. Section 4 states the pregnancy line as applying because "modifying visceral adipose tissue offers no benefit in a pregnant woman and could result in fetal harm." Section 8.4 says safety and effectiveness "in pediatric patients have not been established," and that EGRIFTA SV "is not indicated for use in pediatric patients with open or closed epiphyses."

The warnings on that label name neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity, injection-site reactions, and increased mortality reported after pharmacologic amounts of growth hormone in acute critical illness. The adverse-reaction highlight says the most commonly reported reactions, at greater than 5 percent, were arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia. Those lines keep the brand from being reduced to one friendly sentence. They are not instructions, and this article does not tell anyone how to monitor, inject, or stop a medicine.

The dosage-and-administration section of the same label contains a dose and preparation steps. None of that is copied here. Copying it would turn a prescription label into steps for a different object. The omission is deliberate.

A tesamorelin research vial is not Egrifta

A research vial on this shop is not Egrifta. It is not a prescription. It is not the approved product on the DailyMed label above. It is not a Theratechnologies kit, not a single-dose prescription vial with the diluent that label describes, and not a pharmacy dispense.

The object for sale is one 5 mg vial of tesamorelin at $50, or twelve of those vials for $500. The 5 mg figure is the labeled weight of research material. It is not the prescription strength, and it is not a dose taken from the Egrifta label. Purity is at least 99 percent. Fill is within 10 percent of the labeled weight. Sale is to adults 21 and older. The material is not for people or animals. This shop is not a pharmacy. This page is not medical advice.

Someone reading the indication should read it as a sentence about Egrifta SV. Someone reading the price should read it as a price for a research vial. The label's trial measurements stay with the product that was studied under that label. They are not transferred by sharing the ingredient name.

What CNN wrote

The news roundup is What CNN, Fox, and the other outlets wrote. The major page opened for this name is Jacqueline Howard's CNN feature of April 13, 2026. CNN says tesamorelin has been approved by the FDA "to help people with HIV lose excess abdominal fat," which is the same indication the Egrifta label states above, and CNN quotes a physician describing his own use as "off-label." CNN. That sentence is about the approved product. It is not a result for the research vial, and it is not section 2 of the label.

Sources on tesamorelin and Egrifta

DailyMed, EGRIFTA SV (tesamorelin) kit, setid 3d783378-b02d-4f19-99dd-0fc91a042224, packager Theratechnologies Inc., label updated July 29, 2026, including highlights, section 1, section 4, section 5, section 8.4, section 11, and section 12. Section 2 of that label was read and was not reprinted. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224.

Catalog price checked against `catalog.py` before publication: tesamorelin-5mg, name "Tesamorelin 5mg," full name "Tesamorelin," 5000 cents, twelve for 50000 cents.

Research vials. 21 and older. Not for people or animals.

Araştırma flakonları. 21 yaş ve üzeri. İnsanlar veya hayvanlar için değildir. Tıbbi tavsiye değildir.